Biomarkers of renal damage such as urinary CD133+ EVs, which were found to be abnormally low in acute GN and in albuminuric DN, probably reflecting a reduced reservoir of RPCs, could help identify patients more likely to benefit from treatment with renal-derived EVs from healthy donors [194]. This evidence concerns the gene PROM1 and liver dysplastic nodule.